Medicus Pharma completes $5M Yorkville financing, boosts cash by $2.25M

Rhea-AI Filing Summary

Medicus Pharma Ltd. (NASDAQ: MDCX) filed an 8-K reporting that it has drawn the third and final tranche under the May 2, 2025 Securities Purchase Agreement with YA II PN, Ltd. (Yorkville). The company issued a $2.5 million principal debenture on June 17, 2025, delivering $2.25 million in net proceeds. Together with the two earlier debentures of $1.25 million each, Medicus has now issued the full $5 million aggregate principal authorized under the agreement, receiving $4.5 million in aggregate net cash.

The unsecured debentures are guaranteed by all subsidiaries via a global guaranty agreement. Key terms include:

• Coupon: 8.0% per annum, increasing to 18.0% if an event of default occurs.
• Maturity date: February 2, 2026 (≈ 7.5 months tenor remaining).

Item 2.03 confirms the debt constitutes a direct financial obligation. No equity conversion feature is disclosed, so the financing is presently purely debt-based, increasing leverage but avoiding immediate equity dilution. The filing does not state use of proceeds, financial covenants or repayment schedule beyond maturity.

Implications: The transaction immediately strengthens cash reserves, potentially funding pipeline or operating needs, but adds short-term debt bearing a relatively high interest rate and default step-up. Investors should assess Medicus’ liquidity profile, ability to service the 8% coupon and to refinance or repay $5 million by early 2026.

Positive

• $2.25 million fresh cash increases immediate liquidity, extending operating runway.
• Debt financing avoids near-term equity dilution, preserving existing shareholder ownership.
• Subsidiary guarantees may facilitate future access to credit by establishing lending structure.

Negative

• Total principal debt now at $5 million with 8% coupon, raising interest burden.
• Short maturity (Feb 2026) creates refinancing pressure within nine months.
• Default interest could jump to 18%, indicating lender views company as higher risk.

Insights

Financial Analyst

TL;DR: Adds $2.25 m cash, raises debt to $5 m; short-term 8% coupon—liquidity boost but higher leverage.

The completion of the Yorkville facility secures the full $4.5 million net the company sought, suggesting urgent funding needs ahead of clinical or operating milestones. At 8%, the coupon is moderate for small-cap biotech debt, yet the 18% default step-up underscores lender risk perceptions. With maturity in February 2026, management has less than nine months to generate cash flow, raise equity or refinance. This improves near-term liquidity but compresses medium-term flexibility. Lack of stated covenants is positive; however, subsidiary guarantees elevate structural subordination for unsecured noteholders. Net effect is mixed—cash runway improves, leverage and interest burden rise.

Credit Risk Analyst

TL;DR: Guarantees broaden security, but 8-K signals higher refinancing risk by Q1-26.

The debentures are senior obligations guaranteed by all subsidiaries, strengthening creditor position. Yet a bullet maturity in early 2026 concentrates refinancing risk, particularly if product milestones slip. The 8% rate (potentially 18%) implies speculative-grade credit. Total debt is manageable in absolute dollars but material relative to Medicus’ current market cap (~$30-40 m) and negligible revenue base. Given the biotech sector’s cash-burn profile, investors should monitor covenant triggers and liquidity forecasts. Impact classified neutral: positive liquidity offset by leverage expansion.

8-K Event Classification

3 items: 1.01, 2.03, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 2025-06-17 0001997296 Medicus Pharma Ltd. 0001997296 2025-06-17 2025-06-17 0001997296 exch:XNCM mdcx:CommonSharesNoParValueMember 2025-06-17 2025-06-17 0001997296 exch:XNCM mdcx:WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember 2025-06-17 2025-06-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario	001-42408	98-1778211
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common shares, no par value		MDCX		NASDAQ Capital Market
Warrants, each exercisable for one common share at an exercise price of $4.64 per share		MDCXW		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

Third Debenture

As previously disclosed on May 5, 2025 in that certain Current Report on Form 8-K filed by Medicus Pharma Ltd., a company incorporated under the laws of the Province of Ontario, Canada (the "Company"), the Company entered into a securities purchase agreement (the "Purchase Agreement") with YA II PN, Ltd. ("Yorkville") on May 2, 2025, in connection with the issuance and sale by the Company of debentures (the "Debentures") issuable in an aggregate principal amount of up to $5,000,000. Yorkville purchased and the Company issued a Debenture in aggregate principal amount of $1,250,000 upon the signing of the Purchase Agreement, for net proceeds to the Company of $1,125,000. As previously disclosed in that certain Current Report on Form 8-K filed by the Company on June 2, 2025, Yorkville purchased and the Company issued a second Debenture in aggregate principal amount of $1,250,000 upon the achievement of certain triggers in the Purchase Agreement, for net proceeds to the Company of $1,125,000. On June 17, 2025, Yorkville purchased and the Company issued a third Debenture in aggregate principal amount of $2,500,000, such amount being the remaining amount available pursuant to the Purchase Agreement, for net proceeds to the Company of $2,250,000, and aggregate net proceeds to the Company of $4,500,000 for the issuance of three Debentures in the total aggregate principal amount of $5,000,000. The Debentures are guaranteed by each of the Company's subsidiaries pursuant to a global guaranty agreement (the "Guaranty"). Interest will accrue on the outstanding principal amount of each Debenture at an annual rate of 8.00%, subject to a potential increase to 18.00% per annum upon the occurrence of certain events of default. The Debentures will mature on February 2, 2026.

The foregoing descriptions of the Purchase Agreement, Guaranty and Debentures do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, and with respect to the Debentures, a form thereof, which were filed as Exhibits 10.1, 10.2 and 4.1, respectively, to that certain Current Report on Form 8-K filed by the Company on May 5, 2025, and are incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein in its entirety.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
4.1*		Form of Debenture (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, filed on May 5, 2025).
10.1*		Securities Purchase Agreement, by and between Medicus Pharma Ltd. and YA II PN, Ltd., dated May 2, 2025 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on May 5, 2025).
10.2*		Global Guaranty Agreement, by and among the subsidiaries of Medicus Pharma Ltd. set forth in Schedule I thereto, dated May 2, 2025 (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, filed on May 5, 2025).
104		Cover Page Interactive Data File (formatted as Inline XBRL document).
*		Previously filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.
By:	/s/ Raza Bokhari
Name:	Dr. Raza Bokhari
Title:	Executive Chairman and Chief Executive Officer

Dated: June 20, 2025

FAQ

How much new funding did Medicus Pharma (MDCX) receive on 17 June 2025?

$2.25 million in net proceeds from a $2.5 million principal debenture.

What is the total principal amount of debentures issued to Yorkville?

Medicus has issued $5 million in aggregate principal across three debentures.

What interest rate do the Medicus debentures carry?

They accrue interest at 8.0% annually, rising to 18.0% upon default events.

When do the Medicus Pharma debentures mature?

All three debentures mature on February 2, 2026.

Are Medicus Pharma’s subsidiaries liable for the debentures?

Yes, the debt is guaranteed by each subsidiary through a global guaranty agreement.

Does the new financing dilute existing MDCX shareholders?

No dilution is mentioned; the transaction is debt-based, not equity-linked.